MARKET

CNTA

CNTA

Centessa Pharmaceuticals Plc
NASDAQ
39.59
-0.01
-0.03%
After Hours: 39.59 0 0.00% 16:10 05/15 EDT
OPEN
39.60
PREV CLOSE
39.60
HIGH
39.62
LOW
39.56
VOLUME
533.37K
TURNOVER
--
52 WEEK HIGH
40.26
52 WEEK LOW
10.95
MARKET CAP
6.13B
P/E (TTM)
-22.3951
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Centessa Pharmaceuticals (CNTA) and Radnet (RDNT)
TipRanks · 4d ago
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
Barchart · 4d ago
Weekly Report: what happened at CNTA last week (0504-0508)?
Weekly Report · 4d ago
Alkermes price target raised to $50 from $45 at Needham
TipRanks · 05/07 03:49
Weekly Report: what happened at CNTA last week (0427-0501)?
Weekly Report · 05/04 10:23
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After Its 192% One-Year Surge?
Simply Wall St · 05/01 18:54
Weekly Report: what happened at CNTA last week (0420-0424)?
Weekly Report · 04/27 10:27
Eli Lilly price target raised to $1,183 from $1,163 at Guggenheim
TipRanks · 04/22 11:58
More
About CNTA
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.

Webull offers Centessa Pharmaceuticals PLC - ADR stock information, including NASDAQ: CNTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CNTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CNTA stock methods without spending real money on the virtual paper trading platform.